Slide 1: Oncoinvent: June data update
Oncoinvent Transforming cancer care through direct alpha therapy Targeting by proximity, brilliant in its simplicity June data update
Slide 2: Background, Data Update, Upcoming Milestones
Background Data Update Upcoming Milestones
Slide 3: Ongoing clinical development
Ongoing clinical development 1H25 2H25 1H26 2H26 1H27 2H27 1H28 2H28 Ovarian Ph 1/2a Colorectal Ph 2 Ovarian N = 96 = Interim read-out = Final results
Slide 4: Peritoneal metastases in colorectal cancer – a challenge for caregivers
Peritoneal metastases in colorectal cancer – a challenge for caregivers Challenge: o Present in up to 25% of all Standard of care: Typical effect of patients with colorectal cancer - at initial diagnosis standard of care: or during the disease o Selected patients are offered course Despite surgery a
Slide 5: Peritoneal disease drives survival in colorectal cancer
Peritoneal disease drives survival in colorectal cancer Of patients who experience disease recurrence: 1/3 Peritoneal only Median overall survival - from the time of recurrence: • After distant metastasis only: 44 months • After peritoneal metastasis: 22 months 1/3 Combined peritoneal and 5-year ove
Slide 6: Design: Phase 1/2a in colorectal cancer
Design: Phase 1/2a in colorectal cancer The trial: (RAD-18-002) Radspherin after Two clinical sites: cytoreductive surgery and HIPEC in patients with peritoneal metastasis from colorectal cancer • Oslo, Norway (PI: Stein Larsen) • Uppsala, Sweden (PI: Wilhelm Graf) • Single-arm open label study • 3
Slide 7: Background, Data Update, Upcoming Milestones
Background Data Update Upcoming Milestones
Slide 8: Final data confirms peritoneal control in colorectal cancer
Final data confirms peritoneal control in colorectal cancer Topline 18-months data of 36 patients receiving 7 MBq dose vs historical recurrence rates Peritoneal recurrence rate Radspherin® Historical control The aim of Radspherin® treatment is to avoid or 27.8% 50 % delay peritoneal disease recurren
Slide 9: Principal investigators
Principal investigators "It’s highly encouraging to see patients treated with Radspherin Dr. Stein Gunnar Larsen achieving outcomes that exceed expectations for this challenging population. As a clinician, I’m hopeful that this promising therapy will Principal Investigator at the Oslo University Hos
Slide 10: Favorable safety profile demonstrated across all dose levels (N=47)
Favorable safety profile demonstrated across all dose levels (N=47) • No dose limiting toxicities were observed, no deaths or Well tolerated and safe to use discontinuations due to adverse events were reported • Two out of 25 serious adverse events were reported as possibly related to both Radspheri
Slide 11: Conclusions
Conclusions Safety Efficacy What this means Safety is a key concern in Data demonstrate Data confirm mode of radiopharmaceutical cancer sustained and meaningful action in largest data set to treatment effect in an area of date; strengthening case for enormous unmet medical Radspherin in colorectal T
Slide 12: Background, Data Update, Upcoming Milestones
Background Data Update Upcoming Milestones
Slide 13: Near-term significant milestones
Near-term significant milestones Final 18 months data Phase 1/2a 36 patients 7 MBq colorectal cancer Late 1H25 Final 24 months data Phase 1 10 patients 7 MBq ovarian cancer 2H25 Interim 9 months data Phase 2 Based on analysis of patients recruited by early 2026 ovarian cancer Late 2H26
Slide 14: Ongoing clinical development
Ongoing clinical development 1H25 2H25 1H26 2H26 1H27 2H27 1H28 2H28 Ovarian Ph 1/2a Colorectal Ph 2 Ovarian N = 96 = Interim read-out = Final results
Slide 15: Primary indication: ovarian cancer
Primary indication: ovarian cancer 18 months data from patients receiving 7 MBq dose vs historical recurrence rate Overall recurrence rate RAD-18-001 (10 patients) “I am proud to be part of a study vs historical control program exploring whether Radspherin® may become a Radspherin® Historical contro
Slide 16: Phase 2 study in ovarian cancer – enrollment started
Phase 2 study in ovarian cancer – enrollment started All 6 centers active Patients PFS pPFS • with peritoneal SoC+ Radspherin Assessment OS metastases Randomised (60 patients) every 3 months TFST Safety run-in • after neoadjuvant (6 patients) cohort 2:1 up to 24 TSST chemotherapy (90 patients) month
Slide 17: Financial Calendar
Financial Calendar 27 August Half-year report Q2-25 20 November Company update Q3-25
Slide 18: A unique radiopharmaceutical opportunity
SUMMARY A unique radiopharmaceutical opportunity 1 Targeted, non-biological, receptor independent mode of action with alpha emitter 1 2 In Phase 2 in ovarian cancer 2 3 Signals of efficacy: potential game changer in ovarian and colorectal cancers 3 4 High unmet need and limited competition 4 5 Compa